Protagonist Therapeutics Inc diskutieren
Protagonist Therapeutics Inc
WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Aktie / Micro Cap /
21,80 €
-
Buy Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target lowered by analysts at JPMorgan Chase & Co. from $36.00 to $34.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $32.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $34.00 to $37.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Neueste Beiträge
BMO_Capital_Markets in Canadian Imperial Bank of Commerce diskutieren